NASDAQ: AADIAadi Bioscience Inc Stock
$4.30-0.54 (-11.16%)
Updated Oct 2, 2023
AADI Price
$4.30
Fair Value Price
$5.57
Market Cap
$105.44M
52 Week Low
$4.16
52 Week High
$14.57
P/E
-1.79x
P/B
0.8x
P/S
8.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.54M
Earnings
-$61.58M
Gross Margin
90.7%
Operating Margin
-284.85%
Profit Margin
-285.9%
Debt to Equity
0.15
Operating Cash Flow
-$58M
Beta
0.55
Next Earnings
Nov 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AADI Overview
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AADI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AADI ($4.30) is undervalued by 22.76% relative to our estimate of its Fair Value price of $5.57 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AADI ($4.30) is significantly undervalued by 22.76% relative to our estimate of its Fair Value price of $5.57 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AADI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AADI due diligence checks available for Premium users.
Be the first to know about important AADI news, forecast changes, insider trades & much more!
AADI News
Valuation
AADI fair value
Fair Value of AADI stock based on Discounted Cash Flow (DCF)
Price
$4.30
Fair Value
$5.57
Undervalued by
22.76%
AADI ($4.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AADI ($4.30) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AADI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AADI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.79x
Industry
14.19x
Market
12.38x
AADI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
5.05x
AADI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AADI's financial health
Profit margin
Revenue
$6.2M
Net Income
-$18.0M
Profit Margin
-289.8%
AADI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AADI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$151.2M
Liabilities
$19.8M
Debt to equity
0.15
AADI's short-term assets ($144.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AADI's short-term assets ($144.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AADI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AADI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$50.6M
Financing
$313.0k
AADI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AADI vs Biotech Stocks
Aadi Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.